Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients

Journal of Nephrology

Volumn 22, Issue 5, 2009, Pages 616-622

  Coen, Giorgio ^a,c   Mantella, Daniela ^b   Sardella, Daniela ^a   Beraldi, Maria Pia ^b   Ferrari, Irene ^b   Pierantozzi, Andrea ^a   Lippi, Basilio ^a   Di Giullo, Salvatore ^b  

^a Piazza San Bartolomeo All'Isola 21   (Italy)

^b Hospital of Forlanini   (Italy)

^c NONE   (Italy)

Author keywords

ADMA; Calcification scores; Multislice CT; PTH; Vascular calcifications

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD VESSEL CALCIFICATION; BODY MASS; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE; ARGININE; BODY MASS INDEX; CALCINOSIS; CALCIUM; CORONARY ARTERY DISEASE; CORONARY VESSELS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; REGRESSION ANALYSIS; RENAL DIALYSIS; YOUNG ADULT;

EID: 70649100165     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease. The Mild to Moderate Kidney Disease Study. J Am Soc Nephrol. 2005;16:2456-2461.
2. Kielstein JT, Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular risk factor and an uremic toxin coming of age? Am J Kidney Dis. 2005;46:186-202.
3. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
4. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal dis-ease: a prospective study. Lancet. 2001;358:2113-2117.
5. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005;16:2449-2455.
6. Xiao ZS, Quarles LD, Chen QQ, et al. Effect of asymmetric dimethylarginine on osteoblastic differentiation. Kidney Int. 2001;60:1699-1704.
7. Fan X, Roy E, Zhu L, et al. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. Endocrinology. 2004;145:751-759.
8. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208-2018.
9. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788-1793.
10. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
11. Coen G, Manni M, Mantella D, et al. Are PTH serum levels predictive of coronary calcifications in haemodialysis patients? Nephrol Dial Transplant. 2007;22:3262-3267.
12. Kalantar-Zadeck K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771-780.
13. Avram MM, Mitman N, Myint MM, Fein P. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis. 2001;38:1351-1357.
14. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15:1943-1951.
15. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004;42:1377-1383.
16. Knez A, Becker A, Becker C, et al. [Detection of coronary calcinosis with multislice spiral computerized tomography: an alternative to electron beam tomography] [article in German]. Z Kardiol. 2002;91:642-649.
17. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl 3):S112-S119.
18. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938-942.
19. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353-362.
20. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial calcification in end stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731-1740.
21. London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens. 2005;14:525-531.
22. Toussaint ND, Kerr PG. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology. 2007;12:500-509.
23. Vidal A, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Calcium paradox of aldosteronism and the role of the parathyroid glands. Am J Physiol Heart Circ Physiol. 2006;290:H286-H294.
24. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ. Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol Renal Physiol. 1998;274:642-649.
25. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A. 2002;99:13527-13532.
26. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99:3092-3095.
27. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006;70:2109-2115.